Kowalski Joseph P, Erickson Brett G, Wu Qiuwen, Li Xinyi, Yoo Sua
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
J Appl Clin Med Phys. 2025 Apr;26(4):e70057. doi: 10.1002/acm2.70057. Epub 2025 Feb 22.
This article investigates the performance of a commercial BeO optically stimulated luminescent (OSL) dosimetry system (myOSLchip, RadPro GmbH International, Remscheid, Germany) through the application of the commissioning framework for luminescent dosimeters as described in the American Association of Physicists in Medicine Task Group 191 (AAPM TG191) report. Initial clinical experiences and dosimetric results are also presented. The following properties of the system were characterized: linearity correction factors ranged from -0.5% to +3% for dose levels spanning 0.1 to 20 Gy. Beam quality correction factors (relative to 6 MV) ranged from -4.5% (2.5FFF) to +4.5% (15MV) for photon beams and +1.9% (6 MeV) to +4.3% (20 MeV) for electron beams. An average (µ) signal loss per reading of -2.13% ± 0.20% was measured, however greater signal loss was observed in the first reading (µ = -2.6% ± 0.46%). An initial decline in individual element sensitivity relative to baseline was observed from 0-15 Gy cumulative dose (µ = -1.98% ± 0.55%), with negligible further deterioration from 15-32 Gy (µ = -2.38% ± 0.85%). Post-irradiation, there was a transient OSL signal which faded with a half-life of 1.8 min; this signal enhancement was +5% at 5 min post-irradiation and +1% at 15 min relative to 24 h. Dosimeter response was not dependent on average dose rate in the range of 100-2500 MU/min. With respect to clinical testing, equal or superior performance compared with aluminum oxide OSLs (nanoDots) is shown for a range of clinical techniques and modalities including TSET, TBI, en-face electrons, and pacemaker/out-of-field measurements. The feasibility of myOSLchip to serve as a primary clinical in vivo dosimetry system and direct replacement for Landauer's microStar system is demonstrated.
本文通过应用美国医学物理学家协会任务组191（AAPM TG191）报告中所述的发光剂量计调试框架，研究了一种商用氧化铍光激发发光（OSL）剂量测定系统（myOSLchip，RadPro GmbH International，德国雷姆沙伊德）的性能。还介绍了初步的临床经验和剂量测定结果。对该系统的以下特性进行了表征：对于0.1至20 Gy的剂量水平，线性校正因子范围为-0.5%至+3%。光子束的射束质量校正因子（相对于6 MV）范围为-4.5%（2.5FFF）至+4.5%（15MV），电子束的范围为+1.9%（6 MeV）至+4.3%（20 MeV）。每次读数的平均（µ）信号损失为-2.13%±0.20%，然而在第一次读数中观察到更大的信号损失（µ=-2.6%±0.46%）。从累积剂量0 - 15 Gy观察到相对于基线的单个元件灵敏度初始下降（µ=-1.98%±0.55%），从15 - 32 Gy进一步恶化可忽略不计（µ=-2.38%±0.85%）。辐照后，存在一个瞬态OSL信号，其半衰期为1.8分钟衰减；相对于24小时，该信号增强在辐照后5分钟时为+5%，在15分钟时为+1%。剂量计响应在100 - 2500 MU/分钟范围内不依赖于平均剂量率。关于临床测试，对于一系列临床技术和模式，包括全身电子线照射（TSET）、全身照射（TBI）、表面电子线照射、起搏器/野外测量，显示出与氧化铝OSL（nanoDots）相当或更优的性能。证明了myOSLchip作为主要临床体内剂量测定系统并直接替代Landauer's microStar系统的可行性。
